Literature DB >> 18651508

Smokers versus non-smokers undergoing percutaneous transluminal coronary angioplasty: The impact of clinical and procedural characteristics on in-hospital mortality.

Adam Sukiennik, Marek Koziński, Katarzyna Debska-Kozińska, Aldona Kubica, Zofia Grabczewska, Jacek Kubica.   

Abstract

BACKGROUND: We aimed to compare clinical and procedural characteristics of unselected smokers and non-smokers undergoing percutaneous transluminal coronary angioplasty (PTCA) and to assess their impact on in-hospital mortality.
METHODS: One thousand consecutive patients treated interventionally were retrospectively enrolled into a single academic centre registry.
RESULTS: Smokers (n = 631), in comparison to non-smokers (n = 369), were younger and less likely to be hypertensive, diabetic and female gender. History of myocardial infarction and pre-existing heart failure were also less frequent in the group of smokers. Furthermore, univariate analysis revealed more frequent presentation with acute coronary syndromes (ACS), shorter overall duration of PTCA, shorter exposure to X-rays and lower volume of contrast medium administered in smokers than in non-smokers. Conversely, non-smokers were characterized by considerably higher prevalence of multivessel disease, lower completeness of revascularization and worse final epicardial flow in primary PTCA procedures. Moreover, non-smokers experienced higher crude in-hospital mortality than smokers in the setting of unstable angina/non-ST-segment elevation myocardial infarction (0.0% vs. 6.0%, p = 0.0544) and ST-segment elevation myocardial infarction (6.0% vs. 14.0%, p < 0.02). Smoking status, when adjusted for the baseline characteristics, did not possess any predictive value in terms of in-hospital mortality and surrogates of intervention complexity.
CONCLUSIONS: A strong trend towards decreased mortality among smokers undergoing PTCA was observed when compared to non-smokers. However, the survival advantage might be fully explained by the younger age of the smokers, their more favourable clinical characteristics and less extensive coronary atherosclerosis. (Cardiol J 2007; 14: 482-492).

Entities:  

Year:  2007        PMID: 18651508

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  5 in total

1.  Impact of smoking on the outcome of patients treated with drug-eluting stents: 1-year results from the prospective multicentre German Drug-Eluting Stent Registry (DES.DE).

Authors:  Mohammad A Sherif; Christoph A Nienaber; Ralph Toelg; Mohamed Abdel-Wahab; Volker Geist; Steffen Schneider; Jochen Senges; Karl-Heinz Kuck; Ulrich Tebbe; Gert Richardt
Journal:  Clin Res Cardiol       Date:  2010-12-01       Impact factor: 5.460

Review 2.  Association of smoking with restenosis and major adverse cardiac events after coronary stenting: A meta-analysis.

Authors:  Rui-Ting Hu; Jie Liu; You Zhou; Bang-Li Hu
Journal:  Pak J Med Sci       Date:  2015 Jul-Aug       Impact factor: 1.088

3.  Comparison of no-reflow phenomenon after percutaneous coronary intervention for acute myocardial infarction between smokers and nonsmokers.

Authors:  Hassan Shemirani; Faezeh Dehghani Tafti; Afshin Amirpour
Journal:  J Res Med Sci       Date:  2014-11       Impact factor: 1.852

4.  Smoker's Paradox in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Authors:  Tanush Gupta; Dhaval Kolte; Sahil Khera; Prakash Harikrishnan; Marjan Mujib; Wilbert S Aronow; Diwakar Jain; Ali Ahmed; Howard A Cooper; William H Frishman; Deepak L Bhatt; Gregg C Fonarow; Julio A Panza
Journal:  J Am Heart Assoc       Date:  2016-04-22       Impact factor: 5.501

5.  Association between smoking and in-hospital mortality in patients with acute myocardial infarction: results from a prospective, multicentre, observational study in China.

Authors:  Chenxi Song; Rui Fu; Kefei Dou; Yuejin Yang; Jingang Yang; Haiyan Xu; Xiaojin Gao; Hao Wang; Shuai Liu; Xiaoxue Fan
Journal:  BMJ Open       Date:  2019-08-30       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.